A Study of Luspatercept in People With Anemia
A Multicenter Phase 2 Study of Luspatercept in Patients With Anemia Due to Chronic Kidney Disease
Memorial Sloan Kettering Cancer Center
30 participants
Jul 20, 2026
INTERVENTIONAL
Conditions
Summary
The researchers are doing this study to test whether luspatercept works to improve hemoglobin levels in people with anemia caused by chronic kidney disease (CKD). The researchers will also test whether luspatercept is a safe treatment that causes few or mild side effects in participants.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Luspatercept subcutaneous injection once every 3 weeks
Locations(7)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07725497